Phase 4 Study to Assess the Safety of Trastuzumab Deruxtecan, in Indian Patients

A PROSPECTIVE, MULTI-CENTER, PHASE 4, SINGLE ARM STUDY TO ASSESS THE SAFETY OF TRASTUZUMAB DERUXTECAN, AN ANTI-HER2-ANTIBODY DRUG CONJUGATE IN INDIAN PATIENTS WITH UNRESECTABLE OR METASTATIC HER2-POSITIVE BREAST CANCER WHO HAVE RECEIVED A PRIOR ANTI-HER2-BASED REGIMEN

Trial Details

NCT ID
NCT06429761
Phase
PHASE4
Sponsor
AstraZeneca
Status
RECRUITING
Cancer Type
HER2 Positive Breast Cancer
Interventions
  • Trastuzumab deruxtecan
Locations (sample)
  • Bangalore, India|12.97194,77.59369
  • Delhi, India|28.65195,77.23149
  • Kochi, India|9.93988,76.26022
  • Mumbai, India|19.07283,72.88261
  • Pune, India|18.51957,73.85535

Key Eligibility Criteria

  • 1 Participant must be \>18 years of age inclusive, at the time of signing the informed consent.
  • 2 Patients who are willing and capable of giving signed informed consent as described in Appendix A, which includes compliance with the requirement…
  • 3 Participants with pathologically documented breast cancer that:
  • is unresectable or metastatic

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find HER2 Positive Breast Cancer Trials on Trialify →